Spots Global Cancer Trial Database for ly3214996
Every month we try and update this database with for ly3214996 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| LY3214996 +/- HCQ in Pancreatic Cancer | NCT04386057 | Pancreatic Canc... Advanced Cancer | Hydroxychloroqu... LY3214996 | 18 Years - | Dana-Farber Cancer Institute | |
| ERK 1/2 Signaling in Ibrutinib Resistant B-cell Malignancies | NCT04043845 | Chronic Lymphoc... Waldenstrom Mac... Mantle Cell Lym... Marginal Zone L... | Ibrutinib LY3214996 | 18 Years - | Dana-Farber Cancer Institute | |
| A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer | NCT02857270 | Advanced Cancer Metastatic Mela... Metastatic Non-... Colorectal Canc... | LY3214996 Midazolam Abemaciclib Nab-paclitaxel Gemcitabine Encorafenib Cetuximab | 18 Years - | Eli Lilly and Company | |
| ERK 1/2 Signaling in Ibrutinib Resistant B-cell Malignancies | NCT04043845 | Chronic Lymphoc... Waldenstrom Mac... Mantle Cell Lym... Marginal Zone L... | Ibrutinib LY3214996 | 18 Years - | Dana-Farber Cancer Institute | |
| Combination Therapy of RMC-4630 and LY3214996 in Metastatic KRAS Mutant Cancers | NCT04916236 | Pancreatic Canc... Colorectal Canc... Non-small Cell ... KRAS Mutation-R... | RMC-4630 LY3214996 | 18 Years - | The Netherlands Cancer Institute | |
| Combination Therapy of RMC-4630 and LY3214996 in Metastatic KRAS Mutant Cancers | NCT04916236 | Pancreatic Canc... Colorectal Canc... Non-small Cell ... KRAS Mutation-R... | RMC-4630 LY3214996 | 18 Years - | The Netherlands Cancer Institute | |
| A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer | NCT02857270 | Advanced Cancer Metastatic Mela... Metastatic Non-... Colorectal Canc... | LY3214996 Midazolam Abemaciclib Nab-paclitaxel Gemcitabine Encorafenib Cetuximab | 18 Years - | Eli Lilly and Company | |
| LY3214996 Plus Abemaciclib in Recurrent Glioblastoma Patients | NCT04391595 | Glioblastoma GBM Glioma | Abemaciclib LY3214996 | 18 Years - | St. Joseph's Hospital and Medical Center, Phoenix | |
| A Basket Trial of an ERK1/2 Inhibitor (LY3214996) in Combination With Abemaciclib. | NCT04534283 | Cancer Cancer Metastat... BRAF V600E MEK1 Gene Mutat... MEK2 Gene Mutat... ERK Mutation RAF1 Gene Mutat... | Abemaciclib LY3214996 | 18 Years - | Indiana University | |
| LY3214996 +/- HCQ in Pancreatic Cancer | NCT04386057 | Pancreatic Canc... Advanced Cancer | Hydroxychloroqu... LY3214996 | 18 Years - | Dana-Farber Cancer Institute | |
| LY3214996 Plus Abemaciclib in Recurrent Glioblastoma Patients | NCT04391595 | Glioblastoma GBM Glioma | Abemaciclib LY3214996 | 18 Years - | St. Joseph's Hospital and Medical Center, Phoenix | |
| A Basket Trial of an ERK1/2 Inhibitor (LY3214996) in Combination With Abemaciclib. | NCT04534283 | Cancer Cancer Metastat... BRAF V600E MEK1 Gene Mutat... MEK2 Gene Mutat... ERK Mutation RAF1 Gene Mutat... | Abemaciclib LY3214996 | 18 Years - | Indiana University | |
| LY3214996 in Patients With AML Who Are Not Candidates for Standard Therapy | NCT04081259 | Acute Myeloid L... | LY3214996 | 18 Years - | Dana-Farber Cancer Institute |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
